<DOC>
	<DOCNO>NCT01369368</DOCNO>
	<brief_summary>Patients relapse acute leukemia often receive supportive therapy . Our hypothesis combination therapy stabilize disease patient early relapse allogeneic stem cell transplantation . The investigator combine 5-azacitidine 100 mg daily subcutaneously ( day 1-3 ) , valproic acid ( continuous therapy day 1 ) , All-trans retinoic acid ( day 1-14 ) hydroxurea ( continuous treatment day 15 first cycle . Azacitidine ATRA repeat 5 week interval , donor leukocyte infusion day 10 allow second cycle .</brief_summary>
	<brief_title>Treatment Acute Leukemia Relapse After Allotransplantation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>AML relapse within one year transplantation Blood marrow sample possible Expected survival least 4 week No expect drug interaction Informed consent possible Intolerance study drug Serious kidney liver disease Informed consent possible Previous pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>Relapse</keyword>
	<keyword>Disease stabilization , survival</keyword>
</DOC>